Cuban drug Heberprot-P registered in South Korea

– The effective drug is already registered in 24 countries, including Russia, Kuwait, Ukraine, Argentina, Turkey, Vietnam, Malaysia, Mongolia and Colombia.

Havana, Feb 14 (Agencies) The drug Heberprot-P from Cuba, intended for the treatment of patients with diabetic foot ulcers in advanced stages, has just been registered by the South Korean health authorities.

The president of the Business Group of the Biotechnological and Pharmaceutical Industries of the island (BioCubaFarma), Eduardo Martínez, recently highlighted that there is still no other drug in the world like Heberprot-P.

“We have to put it simply, but it is the reality: it is the only one that manages to prevent a diabetic patient from ending up with an amputation despite having stage four or five ulcers on the Wagner scale,” he said.

Heberprot-P is applied three times a week to the ulcer, and the molecule is infiltrated via injection. When granulation is achieved, that is, when the almost dead tissue revives again, the next applications begin to hurt the patient, explained Martínez.

That is why we are trying to achieve new formulations to reduce the number of times that the patient has to go to the clinic to receive the medicine, added the senior manager.

He also highlighted that «improving the effectiveness of Heberprot-P is not easy because it is already very effective», but with the new pharmaceutical form the results are expected to be superior to those of the drug in its current application.

The general director of the CIGB, Marta Ayala, stressed on her part that the scientific community has worked for years in the development of other applications of the product.

«These tasks have already advanced and they are intended to be used either locally in the wound or in a combination of injectable forms, in order to improve the release of the active ingredient in the area of ​​the injury and reduce the number of applications,» Indian.

More than 300,000 patients around the world have benefited from the drug conceived in 1994, while it is now registered in 24 countries, including Russia, Kuwait, Ukraine, Argentina, Turkey, Vietnam, Malaysia, Mongolia and Colombia.